J&J, Vivus deal

Vivus acquired from Johnson & Johnson's Janssen Pharmaceuticals Inc. a group of patents covering topiramate. Janssen will receive an undisclosed upfront payment and is eligible for undisclosed royalties on sales of Vivus' Qsymia phentermine/topiramate for obesity. Vivus has an option to buy out the royalty for an undisclosed amount. Janssen agreed to dismiss a suit against Vivus filed in August in the U.S. District Court for the District of Delaware. ...